

July 15, 2021
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Corporate Officer

TOKYO, July 15, 2021 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced the appointment of a corporate officer by the Company's Board of Directors at a meeting of the board held on July 15, 2021.

Appointment of Corporate Officer

The Company has appointed Mr. Hiroaki Sekinaga to the position of Managing Officer as of July 16, 2021. The appointment will further strengthen the Company's management team to achieve profitability, which is the most important management goal this year. As Head of the Japan Business Unit, Mr. Hiroaki Sekinaga will oversee the sales and marketing organizations and lead the Company's medical representative activities toward achievement of profitability.

Statement from Mr. Sekinaga: "We will strive to provide more comprehensive information about Treakisym® through our medical representatives, to further address the needs of patients and medical professionals."

Statement from Fuminori Yoshida, President and CEO of Symbio: "We welcome Mr. Sekinaga to our management team. With his strong record of achievement and extensive network in the field of hematology, I am confident that he will make a significant contribution to our efforts to attain profitability."

1. Appointment of Corporate Officer

Name	Title
Hiroaki Sekinaga	Corporate Officer, Managing Officer and Head of Japan Business Unit

2. Date of Appointment: July 16, 2021

3. Profile of the newly appointed Corporate Officer

April 1986	Joined Chugai Pharmaceutical Co, Ltd.
April 2000	Headquarter, Pharmaceutical Promotion Dept.
October 2004	Rituximab Product Manager/ Life Cycle Leader
April 2009	Business Leader in Hematology Area
April 2014	Franchise Leader in Hematology Area etc.
July 2021	Joined SymBio as Executive Advisor

[Contact]

Investor Relations, Administrative Division

Tel: +81(0)3 5472 1125